New York, NY -- (SBWIRE) -- 02/06/2013 -- Cannabis Science, Inc. (OTCQB: CBIS) announced its Corporate Operational Guidance for 2013, highlighting a strategic action plan to "bring to market" innovative, cannabinoid-based, life-saving, anti-cancer drugs.
The Company anticipates releasing a variety of cannabinoid-based treatments that already show great promise in fighting HIV-related illnesses like Kaposi's Sarcoma that is on the rise due to the developing resistance to all current classes of anti-retroviral drugs.
The Company has uniquely positioned itself to offer solutions to these worldwide challenges to human health. Cannabis Science, Inc. is at the forefront of cannabinoid research and development for unmet medical needs. The Company works with leading experts in HIV drug development.
Find out where CBIS could be headed by getting the free full report here: http://www.wallstreetreport.net/market-scan/?symbol=CBIS
GrowLife, Inc. (OTCQB: PHOT) CEO Sterling Scott discussed changing attitudes and laws towards medical and recreational marijuana and the resulting effect on the industry on MoneyTV.
MoneyTV is the internationally syndicated television program all about money and what makes it happen, featuring informative interviews with company CEOs, providing insights into their operations and outlooks for their futures.
Growlife Inc., through its subsidiaries, engages in the manufacture and marketing of progressive horticulture and lifestyle products for the indoor gardening industry and specialty markets in the United States and Canada. It offers hi-powered light emitting diode (LED) grow light products for indoor horticulture; energy efficient and ?green? technology for healthy and abundant indoor gardening; wireless monitoring and control equipment to operate grow room functions.
Find out more on PHOT here: http://www.wallstreetreport.net/market-scan/?symbol=PHOT
WallStreetReport.net issues momentum alerts on stocks that can provide gains to day traders. WallStreetReport.net provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more. WallStreetReport.net monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals WallStreetReport.net is often in the know of several large investor awareness campaigns being deployed.
Timing is everything when trading Penny Stocks. Gain an Edge by joining the WallStreetReport.net newsletter and receiving alerts from a Pro-Active team of researchers. Wall Street Report believes traders should have a chance at successfully trading Penny Stocks and invites traders and investors to be part of the Free VIP membership.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.WallStreetReport.net
Disclosure: WallStreetReport.net is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetreport.Net website, for complete risks and disclosures.
BlueLys, its employees, officers, directors, shareholders and affiliates, hold no positions in the above-mentioned stocks.
WALL STREET REPORT
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)